CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review)

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1343-1350

  Safaee, Michael ^a   Clark, Aaron J ^b   Ivan, Michael E ^b   Oh, Michael C ^b   Bloch, Orin ^a   Sun, Matthew Z ^b   Oh, Taemin ^a   Parsa, Andrew T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; CD97; EGF TM7; Invasion

Indexed keywords

CD97 ANTIGEN; G PROTEIN COUPLED RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER FAMILY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; CELL JUNCTION; CELL MIGRATION; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; DENDRITIC CELL; ESOPHAGUS CARCINOMA; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CARCINOMA; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; THYROID CARCINOMA; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIGENS, CD; HUMANS; LEUKOCYTES; NEOPLASMS;

EID: 84885043672     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2075     Document Type: Review

References (78)

1. Yona S, Lin HH, Siu WO, Gordon S and Stacey M: Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 33: 491-500, 2008.
2. Stacey M, Chang GW, Davies JQ, et al: The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 102: 2916-2924, 2003.
3. Yona S, Lin HH, Dri P, et al: Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB J 22: 741-751, 2008.
4. Kwakkenbos MJ, Pouwels W, Matmati M, et al: Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol 77: 112-119, 2005.
5. Chang GW, Davies JQ, Stacey M, et al: CD312, the human adhesion-GPCR EMR2, is differentially expressed during differentiation, maturation, and activation of myeloid cells. Biochem Biophy Res Commun 353: 133-138, 2007.
6. Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC and Tak PP: Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum 42: 650-658, 1999.
7. Matmati M, Pouwels W, van Bruggen R, et al: The human EGF-TM7 receptor EMR3 is a marker for mature granulocytes. J Leukoc Biol 81: 440-448, 2007.
8. Leemans JC, te Velde AA, Florquin S, et al: The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J Immunol 172: 1125-1131, 2004.
9. van Pel M, Hagoort H, Kwakkenbos MJ, Hamann J and Fibbe WE: Differential role of CD97 in interleukin-8-induced and granulocyte-colony stimulating factor-induced hematopoietic stem and progenitor cell mobilization. Haematologica 93: 601-604, 2008.
10. Eichler W, Hamann J and Aust G: Expression characteristics of the human CD97 antigen. Tissue Antigens 50: 429-438, 1997.
11. Hamann J, Vogel B, van Schijndel GM and van Lier RA: The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184: 1185-1189, 1996.
12. Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W and van Lier RA: Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 28: 1701-1707, 1998.
13. Qian YM, Haino M, Kelly K and Song WC: Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 98: 303-311, 1999.
14. Wang T, Ward Y, Tian L, et al: CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105: 2836-2844, 2005.
15. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF and McCarty JH: Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res 71: 6371-6381, 2011.
16. Friedlander DR, Zagzag D, Shiff B, et al: Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Res 56: 1939-1947, 1996.
17. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA and Gladson CL: Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51: 4986-4993, 1991.
18. Chang GW, Stacey M, Kwakkenbos MJ, Hamann J, Gordon S and Lin HH: Proteolytic cleavage of the EMR2 receptor requires both the extracellular stalk and the GPS motif. FEBS Lett 547: 145-150, 2003.
19. Qian F, Boletta A, Bhunia AK, et al: Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc Natl Acad Sci USA 99: 16981-16986, 2002.
20. Krasnoperov V, Lu Y, Buryanovsky L, Neubert TA, Ichtchenko K and Petrenko AG: Post-translational proteolytic processing of the calcium-independent receptor of alpha-latrotoxin (CIRL), a natural chimera of the cell adhesion protein and the G protein-coupled receptor. Role of the G protein-coupled receptor proteolysis site (GPS) motif. J Biol Chem 277: 46518-46526, 2002.
21. Davies JQ, Chang GW, Yona S, Gordon S, Stacey M and Lin HH: The role of receptor oligomerization in modulating the expression and function of leukocyte adhesion-G protein-coupled receptors. J Biol Chem 282: 27343-27353, 2007.
22. Lin HH, Chang GW, Davies JQ, Stacey M, Harris J and Gordon S: Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif. J Biol Chem 279: 31823-31832, 2004.
23. Galle J, Sittig D, Hanisch I, et al: Individual cell-based models of tumor-environment interactions: multiple effects of CD97 on tumor invasion. Am J Pathol 169: 1802-1811, 2006.
24. Davies JQ, Lin HH, Stacey M, et al: Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncol Rep 25: 619-627, 2011.
25. Aust G, Eichler W, Laue S, et al: CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57: 1798-1806, 1997.
26. Aust G, Steinert M, Schutz A, et al: CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol 118: 699-707, 2002.
27. Liu Y, Chen L, Peng SY, Chen ZX and Hoang-Vu C: Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B 6: 913-918, 2005.
28. Steinert M, Wobus M, Boltze C, et al: Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 161: 1657-1667, 2002.
29. Boltze C, Schneider-Stock R, Aust G, et al: CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathology Int 52: 83-88, 2002.
30. Rutkowski MJ, Sughrue ME, Kane AJ, Kim JM, Bloch O and Parsa AT: Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. J Neurooncol 105: 165-171, 2011.
31. Kane AJ, Sughrue ME, Rutkowski MJ, Phillips JJ and Parsa AT: EMR-3: a potential mediator of invasive phenotypic variation in glioblastoma and novel therapeutic target. Neuroreport 21: 1018-1022, 2010.
32. Chidambaram A, Fillmore HL, Van Meter TE, Dumur CI and Broaddus WC: Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. J Neurosurg 116: 843-853, 2012.
33. Ward Y, Lake R, Martin PL, et al: CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene 32: 2726-2738 2013.
34. Liu D, Trojanowicz B, Ye L, et al: The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma. PLoS One 7: e39989, 2012.
35. Ward Y, Lake R, Yin JJ, et al: LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res 71: 7301-7311, 2011.
36. Hamann J, Eichler W, Hamann D, et al: Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J Immunol 155: 1942-1950, 1995.
37. Gray JX, Haino M, Roth MJ, et al: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 157: 5438-5447, 1996.
38. Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG and Stuart D: The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell 82: 131-141, 1995.
39. D'Souza SE, Ginsberg MH and Plow EF: Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 16: 246-250, 1991.
40. Hamann J, Hartmann E and van Lier RA: Structure of the human CD97 gene: exon shuffling has generated a new type of seven-span transmembrane molecule related to the secretin receptor superfamily. Genomics 32: 144-147, 1996.
41. Doolittle RF: Stein and Moore Award address. Reconstructing history with amino acid sequences. Protein Sci 1: 191-200, 1992.
42. Bjarnadottir TK, Geirardsdottir K, Ingemansson M, Mirza MA, Fredriksson R and Schioth HB: Identification of novel splice variants of adhesion G protein-coupled receptors. Gene 387: 38-48, 2007.
43. Lin HH, Stacey M, Saxby C, et al: Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem 276: 24160-24169, 2001.
44. Reinhardt DP, Ono RN, Notbohm H, Muller PK, Bachinger HP and Sakai LY: Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome. J Biol Chem 275: 12339-12345, 2000.
45. Jaspars LH, Vos W, Aust G, Van Lier RA and Hamann J: Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens 57: 325-331, 2001.
46. Veninga H, de Groot DM, McCloskey N, et al: CD97 antibody depletes granulocytes in mice under conditions of acute inflammation via a Fc receptor-dependent mechanism. J Leukoc Biol 89: 413-421, 2011.
47. Wang T, Tian L, Haino M, et al: Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun 75: 1144-1153, 2007.
48. Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J and Spendlove I: Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol 177: 1070-1077, 2006.
49. Abbott RJ, Spendlove I, Roversi P, et al: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem 282: 22023-22032, 2007.
50. Li L, Spendlove I, Morgan J and Durrant LG: CD55 is over-expressed in the tumour environment. Br J Cancer 84: 80-86, 2001.
51. MacLennan IC: Germinal centers. Annu Rev Immunol 12: 117-139, 1994.
52. Groeneveld PH, Erich T and Kraal G: The differential effects of bacterial lipopolysaccharide (LPS) on splenic non-lymphoid cells demonstrated by monoclonal antibodies. Immunology 58: 285-290, 1986.
53. Berney C, Herren S, Power CA, Gordon S, Martinez-Pomares L and Kosco-Vilbois MH: A member of the dendritic cell family that enters B cell follicles and stimulates primary antibody responses identified by a mannose receptor fusion protein. J Exp Med 190: 851-860, 1999.
54. Kop EN, Kwakkenbos MJ, Teske GJ, et al: Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis Rheum 52: 442-450, 2005.
55. Kop EN, Adriaansen J, Smeets TJ, et al: CD97 neutralisation increases resistance to collagen-induced arthritis in mice. Arthritis Res Ther 8: R155, 2006.
56. Hoek RM, de Launay D, Kop EN, et al: Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis Rheum 62: 1036-1042, 2010.
57. Visser L, de Vos AF, Hamann J, et al: Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol 132: 156-163, 2002.
58. Becker S, Wandel E, Wobus M, et al: Overexpression of CD97 in intestinal epithelial cells of transgenic mice attenuates colitis by strengthening adherens junctions. PLoS One 5: e8507, 2010.
59. Wong NA and Pignatelli M: Beta-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 160: 389-401, 2002.
60. Rivard N: Phosphatidylinositol 3-kinase: a key regulator in adherens junction formation and function. Front Biosci 14: 510-522, 2009.
61. Mustafa T, Klonisch T, Hombach-Klonisch S, et al: Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol 24: 285-294, 2004.
62. Han SL, Xu C, Wu XL, Li JL, Liu Z and Zeng QQ: The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis 25: 695-702, 2010.
63. Wu J, Lei L, Wang S, Gu D and Zhang J: Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J Biomed Biotechnol 2012: 587672, 2012.
64. Mustafa T, Eckert A, Klonisch T, et al: Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 14: 108-119, 2005.
65. Mikesch JH, Schier K, Roetger A, Simon R, Buerger H and Brandt B: The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol 28: 223-232, 2006.
66. Spendlove I, Li L, Carmichael J and Durrant LG: Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res 59: 2282-2286, 1999.
67. Hindmarsh EJ and Marks RM: Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol 28: 1052-1062, 1998.
68. Nasu J, Mizuno M, Uesu T, et al: Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol 113: 379-385, 1998.
69. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA and Armitage NC: Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52: 638-642, 2003.
70. Wobus M, Vogel B, Schmucking E, Hamann J and Aust G: N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer 112: 815-822, 2004.
71. Safaee M, Clark AJ, Oh MC, et al: Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS One 8: e62765, 2013.
72. Bates RC, DeLeo MJ III and Mercurio AM: The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 299: 315-324, 2004.
73. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391, 2001.
74. Wobus M, Huber O, Hamann J and Aust G: CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway. Mol Carcinog 45: 881-886, 2006.
75. Xu Y, Gaudette DC, Boynton JD, et al: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1: 1223-1232, 1995.
76. Guo R, Kasbohm EA, Arora P, et al: Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147: 4883-4892, 2006.
77. Kitayama J, Shida D, Sako A, et al: Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 6: R640-R646, 2004.
78. Park JW, Zarnegar R, Kanauchi H, et al: Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15: 222-231, 2005.